Lucira Health, Inc.

Lucira Health’s chapter 11 case is now closed, with the Delaware Bankruptcy Court entering a final decree on April 20, 2026 after the liquidating trustee reported no objection to closing relief and the remaining April 23 hearing was cancelled as unnecessary. The case began on February 22, 2023, when Lucira filed chapter 11 after a liquidity squeeze tied to collapsing COVID-19 test demand, inventory charges, and a delayed FDA path for its combination COVID-19 and influenza test; CFO Richard Narido’s first-day declaration described a company that had achieved meaningful pandemic-era revenue but had cut roughly 68% of its workforce and failed to secure an out-of-court strategic transaction despite outreach to 177 potential partners through Armanino First Day DeclarationDkt. 3.

The restructuring moved onto a liquidation track. Lucira’s operating story was shaped by its portable molecular testing platform, manufacturing commitments, patent portfolio, and remaining tax attributes, but the chapter 11 path ultimately centered on monetization and claims administration rather than a standalone reorganization. The debtor filed an amended chapter 11 plan of liquidation in July 2023, sponsored by Lucira and structured across four classes Amended Chapter 11 Plan of LiquidationDkt. 487.

By April 2026, administration had wound down into case-closing mechanics. The liquidating trustee filed a certificate of no objection after the April 16, 2026 objection deadline passed without responses to the final decree motion Certificate of No ObjectionDkt. 819. The court then entered the final decree, requiring payment of any remaining statutory fees and final post-confirmation reporting within 30 days, while preserving the ability to reopen the case for cause and retaining jurisdiction over implementation and enforcement . With that order entered, the noticed April 23, 2026 hearing was cancelled because the only agenda matter had been resolved .